A study about immunogenicity and safety of Phase 3 and 4 immunization with combined measles-rubella vaccine

Not Applicable

• Conditions: measles and rubella

• Registration Number: JPRN-UMIN000011832
• Lead Sponsor: Konan Kosei Hospital

Brief Summary

We will present the results at the 17th annual meeting of the Japanese Society for Vacccinology on November 30, 2013.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2013-09-06
• Study Start: 2013-09-23
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

We exclude the subjects from whom we could not obtain the paired serum samples (before and 4-6 weeks after the immunization).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Measles HI and NT antibody positive rates and mean titers before and 4-6 weeks after Phase 3 and Phase 4 MR immunization, and rubella HI antibody positive rates and mean titers before and 4-6 weeks after the both immunization. 2) Before and after the both MR immunization, comparison of the antibody positive rates and the mean antibody titers. 3) Incidence of clinical reactions for 4 weeks after the both MR immunization. 4) Morbidity of measles and rubella after the both immunization.